Calidi Biotherapeutics Valuation
| CLDI Stock | 1.45 0.06 4.32% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Calidi Biotherapeutics shows a prevailing Real Value of USD31.07 per share. The current price of the firm is USD1.45. Our model approximates the value of Calidi Biotherapeutics from analyzing the firm fundamentals such as Shares Outstanding of 5.35 M, return on asset of -1.58, and Shares Owned By Institutions of 6.10 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Calidi Biotherapeutics' valuation include:
Price Book 4.397 | Enterprise Value | Enterprise Value Ebitda (1.64) | Price Sales 50.8277 | Enterprise Value Revenue 49.4238 |
Undervalued
Today
Please note that Calidi Biotherapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Calidi Biotherapeutics is based on 3 months time horizon. Increasing Calidi Biotherapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Calidi Biotherapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Calidi Stock. However, Calidi Biotherapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.45 | Real 31.07 | Target 120.0 | Hype 1.42 |
The intrinsic value of Calidi Biotherapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Calidi Biotherapeutics' stock price.
Estimating the potential upside or downside of Calidi Biotherapeutics helps investors to forecast how Calidi stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Calidi Biotherapeutics more accurately as focusing exclusively on Calidi Biotherapeutics' fundamentals will not take into account other important factors: When choosing an evaluation method for Calidi Biotherapeutics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Calidi Biotherapeutics Cash |
|
Calidi Valuation Trend
Calidi Biotherapeutics' real value analysis enables investors to forecast the earnings more efficiently. Using both Calidi Biotherapeutics' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing decisions.
Calidi Biotherapeutics Total Value Analysis
Calidi Biotherapeutics is currently forecasted to have valuation of 6.49 M with market capitalization of 7.76 M, debt of 7.04 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Calidi Biotherapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
6.49 M | 7.76 M | 7.04 M |
Calidi Biotherapeutics Asset Utilization
One of the ways to look at asset utilization of Calidi is to check how much profit was generated for every dollar of assets it reports. Calidi Biotherapeutics shows a negative utilization of assets of -1.58 percent, losing USD0.0158 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Calidi Biotherapeutics shows how discouraging it operates for each dollar spent on its assets.Calidi Biotherapeutics Ownership Allocation
Calidi Biotherapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.Calidi Biotherapeutics Profitability Analysis
Net Loss for the year was (22.21 M) with profit before overhead, payroll, taxes, and interest of 31 K.About Calidi Biotherapeutics Valuation
An absolute valuation paradigm, as applied to Calidi Stock, attempts to find the value of Calidi Biotherapeutics based on its fundamental and basic technical indicators. By analyzing Calidi Biotherapeutics's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Calidi Biotherapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Calidi Biotherapeutics. We calculate exposure to Calidi Biotherapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Calidi Biotherapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -1.5 M | -1.5 M | |
| Pretax Profit Margin | (649.52) | (617.04) | |
| Operating Profit Margin | (591.05) | (561.50) | |
| Net Loss | (649.80) | (617.31) | |
| Gross Profit Margin | (5.85) | (5.56) |
Calidi Biotherapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 664.4 K |
Calidi Biotherapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Calidi Biotherapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Calidi we look at many different elements of the entity such as Calidi's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Calidi Biotherapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Calidi Biotherapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Calidi Biotherapeutics' worth.Complementary Tools for Calidi Stock analysis
When running Calidi Biotherapeutics' price analysis, check to measure Calidi Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calidi Biotherapeutics is operating at the current time. Most of Calidi Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Calidi Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calidi Biotherapeutics' price. Additionally, you may evaluate how the addition of Calidi Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |